Relay Therapeutics (RLAY) Profit After Tax (2019 - 2026)

Relay Therapeutics (RLAY) has reported Profit After Tax for 8 consecutive years, with -$73.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Profit After Tax rose 3.38% year-over-year to -$73.5 million; the TTM figure through Mar 2026 stood at -$272.0 million (up 17.88% YoY), while the FY2025 annual figure was -$274.8 million, up 18.64% from the prior year.
• Profit After Tax retreated to -$73.5 million in Q1 2026 per RLAY's latest filing, from -$54.6 million in the prior quarter.
• Across five years, Profit After Tax topped out at -$54.6 million in Q4 2025 and bottomed at -$98.5 million in Q2 2023.
• Historically, Profit After Tax has averaged -$77.1 million across 5 years, with a median of -$76.8 million in 2022.
• Annual changes were most pronounced in 2022 — Profit After Tax surged 60.3% — and 2023, when it tumbled 51.89%.
• Relay Therapeutics' Profit After Tax stood at -$64.5 million in 2022, then dropped by 29.38% to -$83.5 million in 2023, then gained by 5.73% to -$78.7 million in 2024, then soared by 30.57% to -$54.6 million in 2025, then plunged by 34.42% to -$73.5 million in 2026.
• Business Quant data shows RLAY's Profit After Tax at -$73.5 million in Q1 2026, -$54.6 million in Q4 2025, and -$73.5 million in Q3 2025.